Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
| 4.1302 | |
| 4.01 | |
| - | |
| 4.161 | |
| 3.94 | |
| 3.49-8.9 | |
| 386 M | |
| 97 933 K | |
| 61 508 K | |
| -0.43 | |
| 0.657 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Alector, Inc. --Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progra...
It is doubtless a positive to see that the Alector, Inc. (NASDAQ:ALEC) share price has gained some 35% in the last three months. But that is meagre solace in the face of the shocking decline over thre...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
